ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021
Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.Journal for immunotherapy of cancer · 2025Trial
- Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer.Acta oncologica (Stockholm, Sweden) · 2025Trial
- IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma.Cancer immunology research · 2026Article
- Cancer-Associated Fibroblasts Promote Glucose Metabolic Reprogramming and Progression of Triple-Negative Breast Cancer via Exosomal circFAD104-Mediated Intercellular Communication.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basallike and HER2-enriched breast cancer.medRxiv : the preprint server for health sciences · 2026Article
- The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Metabolic-immunoregulatory subtypes reveal prognostic and therapeutic insights in multiple primary lung cancer.Frontiers in immunology · 2026Article
- Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy.bioRxiv : the preprint server for biology · 2025Article
- Function of antigen-presenting cells in non-small-cell lung cancer (NSCLC).Medical oncology (Northwood, London, England) · 2025Review
- An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates.Advanced pharmaceutical bulletin · 2025Article
- Editorial: Antigen presentation in cancer immune responses.Frontiers in immunology · 2025Article
- Analysis of the causal relationship between immune cells and rheumatoid arthritis from the perspective of genetic variation: a bidirectional two-sample Mendelian randomization study.Advances in rheumatology (London, England) · 2024Review
- Bojungikki-Tang Augments Pembrolizumab Efficacy in Human PBMC-Injected H460 Tumor-Bearing Mice.Life (Basel, Switzerland) · 2024Article
- Statistical analysis of multiple regions-of-interest in multiplexed spatial proteomics data.Briefings in bioinformatics · 2024Article
- Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells.Journal for immunotherapy of cancer · 2024Article
- Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.Oncoimmunology · 2024Article
- mxfda: a comprehensive toolkit for functional data analysis of single-cell spatial data.Bioinformatics advances · 2024Article
- DIMPLE: An R package to quantify, visualize, and model spatial cellular interactions from multiplex imaging with distance matrices.Patterns (New York, N.Y.) · 2023Article
- A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- FunSpace: A functional and spatial analytic approach to cell imaging data using entropy measures.PLoS computational biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionIn patients with NSCLC, the prognostic significance of the tumor microenvironment (TME) immune composition has been revealed using single- or dual-marker staining on sequential tissue sections. Although these studies reveal that relative abundance and localization of immune cells are important parameters, deeper analyses of the NSCLC TME are necessary to refine the potential application of these findings to clinical care. Currently, the complex spatial relationships between cells of the NSCLC TME and potential drivers contributing to its immunologic composition remain unknown.
methodsWe used multispectral quantitative imaging on the lung adenocarcinoma TME in 153 patients with resected tumors. On a single slide per patient, we evaluated the TME with markers for CD3, CD8, CD14, CD19, major histocompatibility complex II (MHCII), cytokeratin, and 4',6-diamidino-2-phenylindole (DAPI). Image analysis, including tissue segmentation, phenotyping, and spatial localization, was performed.
resultsSpecimens wherein greater than or equal to 5% of lung cancer cells expressed MHCII (MHCII
conclusionsLung cancer cell-specific expression of MHCII associates with levels of immune cell infiltration, spatial localization, and activation status within the TME. This suggests that cancer cell-specific expression of MHCII may represent a biomarker for the immune system's recognition and activation against the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.